newsfilter
← Latest News
GlobeNewswire·

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and